Professor Mauro Perretti
Dean for Research and Research Impact SMD and Professor of Immunopharmacology
Centre: Biochemical Pharmacology
Email: firstname.lastname@example.orgTelephone: +44(0) 20 7882 8782
ORCID iD: https://orcid.org/0000-0003-2068-3331
After BSc in Medicinal Chemistry (University in Florence, 1985) and an MSc in Pharmacology and Toxicology (1988), Mauro Perretti started his career at the Sclavo Research Centre under the leadership of Prof Luca Parente. In 1991, he joined Prof Rod Flower at the William Harvey Research Institute, and in 1996 he gained his PhD (LON). Mauro's career has been shaped by fellowships from the Arthritis Research Campaign, a post-doctoral one (1997-2002) followed by a senior fellowship (2002-2007). In 2001 Mauro gained his personal chair by Queen Mary University of London. Centre Lead of the Centre for Biochemical Pharmacology from 2001-to 2013, Mauro acted as Deputy Director of the William Harvey Research Institute from 2006 to 2013, taking on Co-Directorship in the period 2013-2016. In 2015, he became Dean for Research and Research Impact of the Faculty of Medicine and Dentistry. A role that he still holds.
Mauro has published over 370 papers, with >26,000 citations and an H Factor of 90 (Google Scholar, July 2019).
Member of the British Pharmacological Society from 1993 and of the American Society of Investigative Pathology from 2005. He was awarded the Carttlin Prize (1998; Barts Medical College), the Quintiles Prize (2000; BPS) and delivered the Rocha e Silva Lecture (Brazilian Society of Pharmacology 2014). He is Fellow of the British Pharmacological Society (FBPhS, 2004), the Academia Europea (2010) and of the Brazilian Academy of Sciences (2015).
Dr Trini Montero-Melendez (Senior Post-doctoral Fellow), Dr Jose Garrido-Mesa (Post-doctoral Fellow), Dr Bethan L Thomas (Post-doctoral Fellow), Miss Silvia Oggero (PhD Student), Miss Monika Maciuszek (PhD Student), Miss Millie Davan (PhD Student).
Mauro Perretti began his career in inflammation research by studying the process of leukocyte trafficking with a focus on the bioactions of Annexin A1, under the mentorship of Prof Rod Flower FRS. Determining the impact of endogenous Annexin-A1 on human neutrophil biology (NatMed1996) forged the concept of ‘endogenous anti-inflammatory mediators’ (TiPS1997) prompting the appreciation of resolution mechanisms, or their lack, in human inflammatory pathologies. Over the last two decades he has deciphered several mediators and pathways of resolution in the context of arthritis, sepsis and reperfusion injury, making an internationally recognised contribution to the resolution of inflammation research area. Currently, his focus is on pro-resolving receptors to understand their physio-pathology and define their pro-resolving signature with the ultimate aim to inform innovative therapeutic approaches for the treatment of chronic diseases. As such he aims to add Resolution Pharmacology to the textbooks of Pharmacology of next decade (TiPS2015, NatRevRheumatol2017).
For a full list of publist publications here
Nadkarni S, Lashin H, Hollywood J, Dasgupta B, Mason JC, Perretti M. Identification of an activated neutrophil phenotype in polymyalgia rheumatic during steroid treatment: a potential involvement of immune cell cross-talk. Clin Sci (Lond). 2019 Apr 4;133(7):839-851. doi: 10.1042/CS20180415. PMCID: PMC6449535.
Rhys HI, Dell'Accio F, Pitzalis C, Moore A, Norling LV, Perretti M. Neutrophil Microvesicles from Healthy Control and Rheumatoid Arthritis Patients Prevent the Inflammatory Activation of Macrophages. EBioMedicine. 2018 Mar;29:60-69. doi:10.1016/j.ebiom.2018.02.003. PMCID: PMC5925578.
Lashin HMS, Nadkarni S, Oggero S, Jones HR, Knight JC, Hinds CJ, Perretti M. Microvesicle Subsets in Sepsis Due to Community Acquired Pneumonia Compared to Faecal Peritonitis. Shock. 2018 Apr;49(4):393-401. doi: 10.1097/SHK.0000000000000989. PubMed PMID: 28930915.
Perretti M, Cooper D, Dalli J, Norling LV. Immune resolution mechanisms in inflammatory arthritis. Nat Rev Rheumatol. 2017 Feb;13(2):87-99. doi:10.1038/nrrheum.2016.193. PubMed PMID: 28053331.
Gobbetti T, Dalli J, Colas RA, Federici Canova D, Aursnes M, Bonnet D, Alric L, Vergnolle N, Deraison C, Hansen TV, Serhan CN, Perretti M. Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3963-3968. doi: 10.1073/pnas.1617290114. PMID: 28356517.
Headland SE, Jones HR, Norling LV, Kim A, Souza PR, Corsiero E, Gil CD, Nerviani A, Dell'Accio F, Pitzalis C, Oliani SM, Jan LY, Perretti M. Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis. SciTransl Med. 2015 Nov 25;7(315):315ra190. doi: 10.1126/scitranslmed.aac5608. PubMed PMID: 26606969.
Gobbetti T, Coldewey SM, Chen J, McArthur S, leFaouder P, Cenac N, Flower RJ, Thiemermann C, Perretti M. Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18685-90. doi: 10.1073/pnas.1410938111. PubMed Central PMCID: PMC4284560.
- How Microvesicles could revolutionise arthritis treatment
- Microvesicles are key to potential new study for treating arthritis
- New treatment could ease the agony of arthritis: Tiny bubbles made by the body's own cells may slash the need for surgery
- Injection to end pain of arthritis: New treatment will stop agony without side effects
- Neutrophil microvesicles protect cartilage in arthritis